Researcher | Nanjing Medical University | China
Prof Ye-Bo Zhou is a distinguished researcher in cardiovascular physiology, focusing on the pathogenesis and prevention of cardiovascular diseases. With advanced training in Japan and Singapore and a doctorate from Peking University, she has built a strong foundation in investigating the effects of endogenous molecules such as the calcitonin gene-related peptide family, ADM, and IMD on conditions including hypertension, heart failure, vascular calcification, and atherosclerosis. Her research spans both central and peripheral nervous system mechanisms, contributing significantly to understanding cardiovascular regulation. Prof Zhou has successfully led multiple national and provincial research projects, demonstrating leadership in scientific inquiry and innovation. Her work is widely recognized, reflected in high-impact publications and a strong collaborative network. She continues to explore novel therapeutic targets with potential translational applications. According to Scopus, her measurable research impact includes 78 documents, 2,715 citations, and an h-index of 30, underscoring her significant contribution to the field.
Profiles: Scopus
Featured Publications
1. Intermedin1–53 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation. Journal of Molecular and Cellular Cardiology, 2025.
2. Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. Free Radical Biology and Medicine, 2025.
3. Intermedin1-53 improves atherosclerosis by reducing local endothelial damage via AMPK signaling pathway in obese apoE-deficient mice. Journal of Inflammation Research, 2025.
4. Expression and functional characterization of a low-temperature glucanase derived from rumen microbiota of Hu sheep. Journal of the Zhejiang University Agriculture and Life Science, 2024.
5. Adrenomedullin improved endothelial dysfunction via receptor-Akt pathway in rats with obesity-related hypertension. Hypertension Research, 2024.